Novartis AG (NOVN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
669
About the Report
About the Report
Summary
Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers eye care products through its subsidiary, Alcon; and generic medicines and biosimilars through Sandoz. Novartis carries out research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices in the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
Novartis AG (NOVN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Novartis AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 13
List of Figures 19
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
Novartis AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21
Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
Novartis AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23
Novartis AG, Medical Devices Deals, 2012 to YTD 2018 25
Novartis AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 27
Novartis AG, Pharmaceuticals & Healthcare, Deal Details 62
Asset Purchase 62
Novartis Acquires Rare Pediatric Disease Priority Review Voucher from Ultragenyx Pharma for USD130 Million 62
Fougera Pharma Acquires US Rights to Veregen from Medigene 63
Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 64
Sandoz Acquires Product Portfolio of Euro-Pharm International Canada 66
Novartis Acquires Rights to Interleukin-17 from Ensemble Therapeutics 67
Novartis Acquires Rights of PF-06438179 from Pfizer 68
Sandoz Acquires Rights of Biosimilar Infliximab from Pfizer 69
Novartis Pharma Acquires Rights to Ofatumumab for Auto-Immune Indications from GlaxoSmithKline for up to USD1 Billion 70
Teva Pharma May Divest its Assets 71
Novartis Acquires Cancer Drugs Business of GlaxoSmithKline 73
Novartis Pharma Acquires Immunotherapy Manufacturing Facility From Dendreon For USD 43 Million 75
SensoMotoric Sells Ophthalmic Division To Alcon Labs 76
Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 77
Venture Financing 78
Galera Therapeutics Raises USD70 Million in Series C Venture Financing 78
Coda Biotherapeutics Raises USD19 Million in Series A Financing 80
Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 81
Artios Pharma Raises USD83.6 Million in Series B Venture Financing 83
Akouos Raises USD50 Million in Series A Financing 85
Enterprise Therapeutics Raises USD41.1 Million in Series B Venture Financing 87
Oculis Raises USD20.51 Million in Series B Financing 89
Expansion Therapeutics Raises USD55.3 Million in Series A Financing 91
Semma Therapeutics Raises USD114 Million in Series B Financing 93
Perlara Raises USD7.4 Million in Venture Financing 95
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 96
ImaginAb Raises USD7.7 Million in Venture Financing 98
Rani Therapeutics Raises USD39 Million in Series D Financing 99
Homology Medicines Raises USD83.5 Million in Series B Financing 101
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 103
NeuroVia Raises USD14 Million in Series A Financing 105
E-scape Bio Raises Additional USD8 Million in Series A Financing 106
Anaeropharma Science Raises USD13.2 Million in Venture Financing 108
Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 109
ONL Therapeutics Raises USD4.2 Million in Series A Venture Financing 111
Vivet Therapeutics Raises USD41 Million in Series A Venture Financing 112
Cavion Raises USD26 Million in Series A Financing 114
Inflazome Raises USD17 Million in Series A Financing 115
Rox Medical Raises USD40 Million in Series E Financing 116
Annexon Biosciences Raises USD44 Million in Series B Financing 117
IFM Therapeutics Raises USD27 Million in Series A Financing Round 118
F2G Raises USD60 Million in Venture Financing 119
Blade Therapeutics Raises USD27 Million in Series B Financing 121
Caribou Biosciences Raises USD30 Million in Series B Financing Round 123
Ideaya Biosciences Raises USD46 Million in Series A Financing 125
Rani Therapeutics Raises Funds in Financing 127
Galera Therapeutics Raises Additional USD5 Million in Series B Financing 129
Adicet Bio Raises USD51 Million in Series A Financing Round 130
C4 Therapeutics Raises USD73 Million in Series A Financing Round 131
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 132
Galera Therapeutics Raises USD37 Million in Series B Financing 134
Proteostasis Therapeutics Raises USD37 Million in Series B Financing 135
Intellia Therapeutics Raises USD70 Million in Series B Financing 137
Merus Raises USD46.4 Million in First Tranche of Series C Financing 139
Encore Vision Raises USD2.5 Million in Series C Financing 141
E-scape Bio Raises USD55 Million in Series A Financing 142
Ra Pharma Raises USD58.5 Million in Series B Financing 144
Advanced Accelerator Applications Raises USD26 Million in Venture Financing 146
Kanyos Bio Raises USD16 Million in Venture Financing 147
Arcus Biosciences Raises USD50 Million in Series A Financing 148
Rani Therapeutics Raises USD25 Million in Series C Venture Financing 150
Innocrin Pharma Raises USD28 Million in Series D Financing 151
Nabriva Therapeutics Raises USD120 Million in Series B Financing 152
Caribou Biosciences Raises USD11 Million in Series A Financing 154
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 156
Neurovance Raises Additional USD5.5 Million in Venture Financing 157
Macrolide Pharma Raises USD22 Million in Series A Financing 158
Merganser Biotech Raises USD28 Million in Series A Financing 159
Vaxin Raises USD16 Million in Venture Financing 160
Surface Oncology Raises USD35 Million in Series A Financing 161
Annexon Bioscience Raises USD34 Million in Series A-1 Venture Financing 163
Intellia Therapeutics Raises USD15 Million in Series A Venture Financing 164
Ziarco Raises USD33 Million in Series B Venture Financing 165
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 166
Quartet Medicine Raises USD17 Million in Series A Venture Financing 168
Innocrin Pharma Raises Funds through Venture Financing 169
Forendo Pharma Raises USD15.3 Million in Series A Venture Financing 170
Viamet Pharma Raises USD60 Million in Series D Venture Financing 172
Raze Therapeutics Raises USD24 Million in Series A Venture Financing 173
Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 175
Encore Vision Raises USD1.7 Million in Venture Financing 176
Neurovance Raises Additional USD4 Million in Venture Financing 177
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 178
Sorbent Therapeutics Raises USD6.5 Million In First Tranche Of Series D Financing 179
ImaginAb Raises USD21 Million in Series B Venture Financing 180
Anokion Raises USD 37.5 Million In Series A Venture financing 181
Aerpio Therapeutics Raises USD 22 Million In Venture Financing 182
Spinifex Pharma Raises USD6.2 Million in Venture Financing 184
Spinifex Pharma Raises USD 45 Million In Series C Financing 185
Alios BioPharma Raises USD 41 Million In Series B Venture Financing 187
Thesan Pharma Raises USD 49 Million In Series B Venture Financing 188
Covagen Raises USD 50.3 Million In Series B Financing 189
Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 191
Encore Vision Secures USD5 Million in Venture Funding 192
Aileron Therapeutics Raises USD 30 Million In Series E Financing 193
Aerpio Therapeutics Raises USD 9 Million In Extended Series A Financing 195
Merus Raises USD 42 Million In Extended Series B Financing 197
Opsona Therapeutics Raises USD46.8 Million In Extended Series C Financing 199
Akebia Therapeutics Raises USD 41 Million In Series C Financing 201
Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 202
Effector Therapeutics Raises USD 45 Million In Series A Financing 203
Tokai Pharma Raises USD 35.5 Million In Series E Financing 205
Neurovance Raises USD 6 Million In Series A1 Financing 206
GenSight Biologics Raises USD 41.6 Million In Series A Financing 208
Catalyst Biosciences Secures USD5.07 Million in Venture Funding 210
CoStim Pharma Raises USD 10 Million In Venture Financing 212
Aileron Raises USD 12 Million In Extended Series D Financing 213
Bicycle Therapeutics Raises USD 6 Million In Venture Financing 215
Galera Therapeutics Raises USD 11 Million In Series A Financing 217
Ziarco Pharma Raises USD 6 Million In First Tranche Of Series A financing 218
Thesan Pharma Raises Additional USD 12 Million In Series A Financing 219
Qurient Raises USD 4 Million In Venture Financing 220
Selexys Pharma Raises USD 23 Million In Series A Financing 221
F2G Raises USD 30 Million In Venture Financing 222
Aerpio Therapeutics Raises USD 27 Million In Series A Financing 223
PharmAbcine Raises USD 3.5 Million In Series B Financing 224
Ra Pharma Raises USD 8.6 Million In Second Tranche Of Series A Financing 225
Celladon Raises Additional USD 10 Million In Series D Financing 226
BioRelix Raises USD 0.27 Million In Venture Financing 228
Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 229
Akebia Therapeutics Secures Additional USD 4.1 Million In Series B Financing 230
AMP Therapeutics Raises Funds Through Series A Financing 231
Private Equity 232
Samara Capital Partners Acquires Anti-Infective Brands from Novartis 232
Gamida Cell Raises USD40 Million in Private Financing 233
Ampersand Capital Partners and 1315 Capital Acquires Genoptix 235
dievini Hopp BioTech Acquires Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 236
Partnerships 237
Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 237
Pfizer Enters into Co-Development Agreement with Novartis 238
Global Antibiotic Research & Development Partnership Enters into Partnership with Novartis 239
Novartis and Mundipharma Enter into Agreement 240
Novartis and Albumedix Enter into Agreement 241
Pear Therapeutics Enters into Agreement with Sandoz 242
Novartis to Enter into Agreement with Wyss Institute for Biologically Inspired Engineering at Harvard 243
Pear Therapeutics Enters into Agreement with Novartis 244
Novartis and Bill & Melinda Gates Foundation Enter into Partnership 245
Sandoz International Enters into Agreement with Biocon 246
Homology Medicines Enters into Agreement with Novartis 247
Novartis Enters into Agreement with University of California 248
Helsinn Therapeutics Enters into Co-Promotion Agreement with Novartis 249
Cipla and Novartis May Enter into Co-Marketing Agreement 250
Oxford BioMedica Enters into Agreement with Novartis 251
Bristol-Myers Squibb Enters into Partnership with Novartis 252
Allergan Enters into Agreement with Novartis 253
Perthera Enters into Agreement with Novartis 254
TARGET PharmaSolutions Enters into Agreement with Novartis 255
Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 256
Protagen Enters into Agreement with Novartis Pharma 258
Conatus Pharma Enters into Co-Development Agreement with Novartis Pharma 259
Rovi Enters into Co-Marketing Agreement with Novartis for Neparvis 260
Cerulean Pharma Enters into Partnership with Novartis 261
Perlara Enters into Partnership with Novartis 262
Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 263
Cure Forward Partners with Novartis Pharma 264
Novartis Expands its Agreement with Medicines for Malaria Venture 265
Novartis Pharma Enters into Agreement with Eisai 266
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 267
Cigna Enters into Contract with Novartis 268
MedinCell Enters into Agreement with Sandoz International 269
Radius Health Partners with Novartis Pharma for RAD1901 270
NeoBiocon Enters into Agreement with Novartis 271
Accelis Pharma Enters into Distribution Agreement with Fougera Pharma 272
Amgen Expands its Co-Development Agreement with Novartis 273
Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 274
Sosei Plans to Enter into Agreement with Novartis 275
Rani Therapeutics Enters into Agreement with Novartis 276
PaxVax Enters into Distribution Agreement with Novartis 277
Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 278
Semma Therapeutics Enters into Agreement with Novartis 279
Novartis Enters into Co-Development Agreement with Department of Science & Technology 280
PeptiDream Expands Drug Discovery Agreement with Novartis 281
BioLineRx Enters into Agreement with Novartis Pharma 282
Rega Institute for Medical Research, Centre for Drug Design and Discovery, KRICT Enters into Partnership with Novartis 283
Novartis Enters into Licensing Agreement with Ligand Pharma 334
Novartis AG - Key Competitors 506
Novartis AG - Key Employees 507
Novartis AG - Locations And Subsidiaries 509
Head Office 509
Other Locations & Subsidiaries 509
Recent Developments 527
Strategy And Business Planning 527
Oct 30, 2018: Novartis and Pfizer partner to advance NASH therapy 527
Oct 04, 2018: Novartis licences anti-infective candidates to Boston Pharmaceuticals 528
Sep 28, 2018: Novartis signs Chinese manufacturing deal with Cellular Biomedicines for Kymriah 529
Sep 25, 2018: Novartis to cut more than 2000 jobs in Switzerland and UK 530
Sep 25, 2018: Novartis proposes to exit Grimsby UK site by end of 2020 as part of global manufacturing network transformation 531
Sep 11, 2018: Nova Medical Centers opens occupational medicine clinic in El Paso, Texas 532
Sep 06, 2018: Novartis to divest select Sandoz US portfolio to Aurobindo for $900m 533
Jul 02, 2018: Novartis plans to spin-off eye care unit into standalone entity 534
Oct 16, 2017: Novartis to Shut Broomfield Generics Manufacturing Unit, Eliminate 450 Jobs 535
Financial Announcements 536
Oct 18, 2018: Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth 536
Jul 18, 2018: Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company 541
Apr 19, 2018: Novartis delivered a strong first quarter and acted to become a more focused medicines company 546
Jan 24, 2018: Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase 550
Oct 24, 2017: Novartis delivered growth on top and bottom line in all divisions in Q3 558
Jul 18, 2017: Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products 563
Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 568
Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 572
Corporate Communications 578
Aug 14, 2018: Novartis names Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer 578
May 16, 2018: Novartis announces changes to the Executive Committee 579
Apr 19, 2018: Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer 580
Mar 19, 2018: Novartis Foundation joins Global Partnership for Zero Leprosy 581
Mar 12, 2018: Novartis announces changes to the Executive Committee to support strategic priorities 582
Dec 15, 2017: Novartis announces Oncology head to retire 583
List of Figure
List of Figures
Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Novartis AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
Novartis AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 21
Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
Novartis AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23
Novartis AG, Medical Devices Deals, 2012 to YTD 2018 25
List of Table
List of Tables
Novartis AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Novartis AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
Novartis AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21
Novartis AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
Novartis AG, Deals By Therapy Area, 2012 to YTD 2018 23
Novartis AG, Medical Devices Deals, 2012 to YTD 2018 25
Novartis AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 27
Novartis Acquires Rare Pediatric Disease Priority Review Voucher from Ultragenyx Pharma for USD130 Million 62
Fougera Pharma Acquires US Rights to Veregen from Medigene 63
Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 64
Sandoz Acquires Product Portfolio of Euro-Pharm International Canada 66
Novartis Acquires Rights to Interleukin-17 from Ensemble Therapeutics 67
Novartis Acquires Rights of PF-06438179 from Pfizer 68
Sandoz Acquires Rights of Biosimilar Infliximab from Pfizer 69
Novartis Pharma Acquires Rights to Ofatumumab for Auto-Immune Indications from GlaxoSmithKline for up to USD1 Billion 70
Teva Pharma May Divest its Assets 71
Novartis Acquires Cancer Drugs Business of GlaxoSmithKline 73
Novartis Pharma Acquires Immunotherapy Manufacturing Facility From Dendreon For USD 43 Million 75
SensoMotoric Sells Ophthalmic Division To Alcon Labs 76
Sandoz Completes Acquisition Of Four Generic Products From Watson Pharma And Actavis 77
Galera Therapeutics Raises USD70 Million in Series C Venture Financing 78
Coda Biotherapeutics Raises USD19 Million in Series A Financing 80
Twentyeight-Seven Therapeutics Raises USD65 Million in Series A Venture Financing 81
Artios Pharma Raises USD83.6 Million in Series B Venture Financing 83
Akouos Raises USD50 Million in Series A Financing 85
Enterprise Therapeutics Raises USD41.1 Million in Series B Venture Financing 87
Oculis Raises USD20.51 Million in Series B Financing 89
Expansion Therapeutics Raises USD55.3 Million in Series A Financing 91
Semma Therapeutics Raises USD114 Million in Series B Financing 93
Perlara Raises USD7.4 Million in Venture Financing 95
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 96
ImaginAb Raises USD7.7 Million in Venture Financing 98
Rani Therapeutics Raises USD39 Million in Series D Financing 99
Homology Medicines Raises USD83.5 Million in Series B Financing 101
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 103
NeuroVia Raises USD14 Million in Series A Financing 105
E-scape Bio Raises Additional USD8 Million in Series A Financing 106
Anaeropharma Science Raises USD13.2 Million in Venture Financing 108
Bicycle Therapeutics Raises USD51.35 Million in Series B Round of Financing 109
ONL Therapeutics Raises USD4.2 Million in Series A Venture Financing 111
Vivet Therapeutics Raises USD41 Million in Series A Venture Financing 112
Cavion Raises USD26 Million in Series A Financing 114
Inflazome Raises USD17 Million in Series A Financing 115
Rox Medical Raises USD40 Million in Series E Financing 116
Annexon Biosciences Raises USD44 Million in Series B Financing 117
IFM Therapeutics Raises USD27 Million in Series A Financing Round 118
F2G Raises USD60 Million in Venture Financing 119
Blade Therapeutics Raises USD27 Million in Series B Financing 121
Caribou Biosciences Raises USD30 Million in Series B Financing Round 123
Ideaya Biosciences Raises USD46 Million in Series A Financing 125
Rani Therapeutics Raises Funds in Financing 127
Galera Therapeutics Raises Additional USD5 Million in Series B Financing 129
Adicet Bio Raises USD51 Million in Series A Financing Round 130
C4 Therapeutics Raises USD73 Million in Series A Financing Round 131
Effector Therapeutics Raises USD40 Million in Series B Venture Financing 132
Galera Therapeutics Raises USD37 Million in Series B Financing 134
Proteostasis Therapeutics Raises USD37 Million in Series B Financing 135
Intellia Therapeutics Raises USD70 Million in Series B Financing 137
Merus Raises USD46.4 Million in First Tranche of Series C Financing 139
Encore Vision Raises USD2.5 Million in Series C Financing 141
E-scape Bio Raises USD55 Million in Series A Financing 142
Ra Pharma Raises USD58.5 Million in Series B Financing 144
Advanced Accelerator Applications Raises USD26 Million in Venture Financing 146
Kanyos Bio Raises USD16 Million in Venture Financing 147
Arcus Biosciences Raises USD50 Million in Series A Financing 148
Rani Therapeutics Raises USD25 Million in Series C Venture Financing 150
Innocrin Pharma Raises USD28 Million in Series D Financing 151
Nabriva Therapeutics Raises USD120 Million in Series B Financing 152
Caribou Biosciences Raises USD11 Million in Series A Financing 154
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 156
Neurovance Raises Additional USD5.5 Million in Venture Financing 157
Macrolide Pharma Raises USD22 Million in Series A Financing 158
Merganser Biotech Raises USD28 Million in Series A Financing 159
Vaxin Raises USD16 Million in Venture Financing 160
Surface Oncology Raises USD35 Million in Series A Financing 161
Annexon Bioscience Raises USD34 Million in Series A-1 Venture Financing 163
Intellia Therapeutics Raises USD15 Million in Series A Venture Financing 164
Ziarco Raises USD33 Million in Series B Venture Financing 165
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 166
Quartet Medicine Raises USD17 Million in Series A Venture Financing 168
Innocrin Pharma Raises Funds through Venture Financing 169
Forendo Pharma Raises USD15.3 Million in Series A Venture Financing 170
Viamet Pharma Raises USD60 Million in Series D Venture Financing 172
Raze Therapeutics Raises USD24 Million in Series A Venture Financing 173
Bicycle Therapeutics Raises USD32 Million in Series A Venture Financing 175
Encore Vision Raises USD1.7 Million in Venture Financing 176
Neurovance Raises Additional USD4 Million in Venture Financing 177
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 178
Sorbent Therapeutics Raises USD6.5 Million In First Tranche Of Series D Financing 179
ImaginAb Raises USD21 Million in Series B Venture Financing 180
Anokion Raises USD 37.5 Million In Series A Venture financing 181
Aerpio Therapeutics Raises USD 22 Million In Venture Financing 182
Spinifex Pharma Raises USD6.2 Million in Venture Financing 184
Spinifex Pharma Raises USD 45 Million In Series C Financing 185
Alios BioPharma Raises USD 41 Million In Series B Venture Financing 187
Thesan Pharma Raises USD 49 Million In Series B Venture Financing 188
Covagen Raises USD 50.3 Million In Series B Financing 189
Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 191
Encore Vision Secures USD5 Million in Venture Funding 192
Aileron Therapeutics Raises USD 30 Million In Series E Financing 193
Aerpio Therapeutics Raises USD 9 Million In Extended Series A Financing 195
Merus Raises USD 42 Million In Extended Series B Financing 197
Opsona Therapeutics Raises USD46.8 Million In Extended Series C Financing 199
Akebia Therapeutics Raises USD 41 Million In Series C Financing 201
Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 202
Effector Therapeutics Raises USD 45 Million In Series A Financing 203
Tokai Pharma Raises USD 35.5 Million In Series E Financing 205
Neurovance Raises USD 6 Million In Series A1 Financing 206
GenSight Biologics Raises USD 41.6 Million In Series A Financing 208
Catalyst Biosciences Secures USD5.07 Million in Venture Funding 210
CoStim Pharma Raises USD 10 Million In Venture Financing 212
Aileron Raises USD 12 Million In Extended Series D Financing 213
Bicycle Therapeutics Raises USD 6 Million In Venture Financing 215
Galera Therapeutics Raises USD 11 Million In Series A Financing 217
Ziarco Pharma Raises USD 6 Million In First Tranche Of Series A financing 218
Thesan Pharma Raises Additional USD 12 Million In Series A Financing 219
Qurient Raises USD 4 Million In Venture Financing 220
Selexys Pharma Raises USD 23 Million In Series A Financing 221
F2G Raises USD 30 Million In Venture Financing 222
Aerpio Therapeutics Raises USD 27 Million In Series A Financing 223
PharmAbcine Raises USD 3.5 Million In Series B Financing 224
Ra Pharma Raises USD 8.6 Million In Second Tranche Of Series A Financing 225
Celladon Raises Additional USD 10 Million In Series D Financing 226
BioRelix Raises USD 0.27 Million In Venture Financing 228
Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 229
Akebia Therapeutics Secures Additional USD 4.1 Million In Series B Financing 230
AMP Therapeutics Raises Funds Through Series A Financing 231
Samara Capital Partners Acquires Anti-Infective Brands from Novartis 232
Gamida Cell Raises USD40 Million in Private Financing 233
Ampersand Capital Partners and 1315 Capital Acquires Genoptix 235
dievini Hopp BioTech Acquires Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 236
Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 237
Pfizer Enters into Co-Development Agreement with Novartis 238
Global Antibiotic Research & Development Partnership Enters into Partnership with Novartis 239
Novartis and Mundipharma Enter into Agreement 240
Novartis and Albumedix Enter into Agreement 241
Pear Therapeutics Enters into Agreement with Sandoz 242
Novartis to Enter into Agreement with Wyss Institute for Biologically Inspired Engineering at Harvard 243
Pear Therapeutics Enters into Agreement with Novartis 244
Novartis and Bill & Melinda Gates Foundation Enter into Partnership 245
Sandoz International Enters into Agreement with Biocon 246
Homology Medicines Enters into Agreement with Novartis 247
Novartis Enters into Agreement with University of California 248
Helsinn Therapeutics Enters into Co-Promotion Agreement with Novartis 249
Cipla and Novartis May Enter into Co-Marketing Agreement 250
Oxford BioMedica Enters into Agreement with Novartis 251
Bristol-Myers Squibb Enters into Partnership with Novartis 252
Allergan Enters into Agreement with Novartis 253
Perthera Enters into Agreement with Novartis 254
TARGET PharmaSolutions Enters into Agreement with Novartis 255
Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 256
Protagen Enters into Agreement with Novartis Pharma 258
Conatus Pharma Enters into Co-Development Agreement with Novartis Pharma 259
Rovi Enters into Co-Marketing Agreement with Novartis for Neparvis 260
Cerulean Pharma Enters into Partnership with Novartis 261
Perlara Enters into Partnership with Novartis 262
Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 263
Cure Forward Partners with Novartis Pharma 264
Novartis Expands its Agreement with Medicines for Malaria Venture 265
Novartis Pharma Enters into Agreement with Eisai 266
Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 267
Cigna Enters into Contract with Novartis 268
MedinCell Enters into Agreement with Sandoz International 269
Radius Health Partners with Novartis Pharma for RAD1901 270
NeoBiocon Enters into Agreement with Novartis 271
Accelis Pharma Enters into Distribution Agreement with Fougera Pharma 272
Amgen Expands its Co-Development Agreement with Novartis 273
Medicines Company Enters into Distribution Agreement with Sandoz for Angiomax 274
Novartis AG, Key Competitors 506
Novartis AG, Key Employees 507
Novartis AG, Subsidiaries 509
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.